Joining Jack News
£1 million to fund the next three years of DMD Care
To mark Rare Disease Day 2024 Alex and the Joining Jack team took part in a series of collaborative meetings: the first to address the work we are doing in harnessing technology to help disability and the second was to continue to drive forward our amazing DMD Care UK programme, to ensure boys get the best care, no matter where they live.
First treatment for all patients with DMD approved in UK
We are delighted to welcome the news that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved vamorolone (sold under the brand name Agamree) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older.
New, decentralised study to validate new, home-based video assessment of DMD
Decentralised study to validate new, home-based video assessment of Duchenne
Santhera has applied for marketing authorisation to the European Medical Agency for the drug vamorolone.
We partnered with Whizz-Kidz and the University of Edinburgh to win £1 million from the People’s Postcode Lottery Dream Fund to develop a dream chair for wheelchair users